People's Hospital Of Yichang Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2015
NCT02965092
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

People Hospital Of Yichang | People's Hospital Of Yichang | Yichang Central People's Hospital | Yichang City Central People's Hospital

Active Ingredients

Drugs in Phase 3 Trials (2)

borneol (1 trial)

capecitabine (xeloda) (1 trial)

Drugs in Phase 2 Trials (1)

cd19 car-t cells (3 trials)

Drugs in Other Trials (2)

propofol (diprivan) (1 trial)

remimazolam (Byfavo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 5